InvestSMART

Emyria Limited (ASX: EMD) - Announcements

- Current share price for EMD : $0.032

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$26 Appendix 4G 29 Aug 2022 6:55PM $0.255 $0.032 fallen by 87.45%
$26 Appendix 4E and Annual Report 29 Aug 2022 6:55PM $0.255 $0.032 fallen by 87.45%
$26 Positive results received for Emyrias MDMA-inspired program 18 Aug 2022 9:27AM $0.255 $0.032 fallen by 87.45%
$26 Notification regarding unquoted securities - EMD 17 Aug 2022 7:27PM $0.255 $0.032 fallen by 87.45%
$26 Emyria receives ethics approval for EMD-RX5 Phase 3 trial 16 Aug 2022 9:45AM $0.245 $0.032 fallen by 86.94%
$26 Preclinical studies initiated for MDMA-inspired analogues 4 Aug 2022 9:54AM $0.215 $0.032 fallen by 85.12%
$26 Appendix 4C - Quarterly 28 Jul 2022 11:24AM $0.215 $0.032 fallen by 85.12%
$26 Emyria expands drug candidate library inspired by MDMA 18 Jul 2022 8:19AM $0.220 $0.032 fallen by 85.45%
$26 Notification regarding unquoted securities - EMD 9 Jun 2022 9:21AM $0.250 $0.032 fallen by 87.20%
$26 Drug development webinar presentation 1 Jun 2022 5:23PM $0.275 $0.032 fallen by 88.36%
$26 Emyria expands MDMA analogue program with UWA 31 May 2022 9:45AM $0.270 $0.032 fallen by 88.15%
$26 Emyria Investor Webinar, June 1st 30 May 2022 12:56PM $0.275 $0.032 fallen by 88.36%
$26 EMD-RX5 demonstrates excellent safety and bioavailability 25 May 2022 9:30AM $0.300 $0.032 fallen by 89.33%
$26 Trading Halt 23 May 2022 9:08AM $0.300 $0.032 fallen by 89.33%
$26 Further positive MDMA analogue screening results received 10 May 2022 8:38AM $0.250 $0.032 fallen by 87.20%
$26 Appendix 4C - Quarterly 27 Apr 2022 9:44AM $0.305 $0.032 fallen by 89.51%
$26 Results of Meeting 20 Apr 2022 1:22PM $0.340 $0.032 fallen by 90.59%
$26 Change of Director's Interest Notice MW 20 Apr 2022 9:28AM $0.330 $0.032 fallen by 90.30%
$26 EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial 14 Apr 2022 9:47AM $0.305 $0.032 fallen by 89.51%
$26 Clinitrials to lead multi-site Phase 3 trial for EMD-RX5 13 Apr 2022 9:22AM $0.300 $0.032 fallen by 89.33%
$26 Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial 7 Apr 2022 9:45AM $0.310 $0.032 fallen by 89.68%
$26 Broker Briefing Presentation 24 Mar 2022 3:09PM $0.330 $0.032 fallen by 90.30%
$26 Emyria to present webinar, March 24th 23 Mar 2022 9:32AM $0.345 $0.032 fallen by 90.72%
$26 Letter to Shareholders - Adjourned General Meeting 18 Mar 2022 6:19PM $0.325 $0.032 fallen by 90.15%
$26 Addendum to Notice of Meeting and Proxy Form 18 Mar 2022 6:16PM $0.325 $0.032 fallen by 90.15%

351 - 375 of 583 results

Page 15 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.